A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-versus-Host Disease Involving the Lower Gastrointestinal Tract

Trial Profile

A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-versus-Host Disease Involving the Lower Gastrointestinal Tract

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs ALXN 1007 (Primary)
  • Indications Graft-versus-host disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GIGVHD
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 27 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Feb 2017.
    • 27 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top